NovoCure Ltd 8-K

What Happened

• NovoCure Ltd announced on February 11, 2026 (via an 8-K, Item 7.01) that the U.S. Food and Drug Administration (FDA) has approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer when used concomitantly with gemcitabine and nab‑paclitaxel. The company issued a press release (Exhibit 99.1) to disclose the approval under Regulation FD.

Key Details

• FDA approval announced: February 11, 2026.
• Approved indication: adult patients with locally advanced pancreatic cancer, to be used concomitantly with gemcitabine and nab‑paclitaxel.
• Filing type: Form 8-K under Item 7.01 (Regulation FD Disclosure); the report states the information is not deemed “filed” for purposes of Section 18 of the Exchange Act.
• Exhibit and signature: Press release attached as Exhibit 99.1; Form 8-K signed by CFO Christoph Brackmann.

Why It Matters

• FDA approval is a regulatory milestone that authorizes NovoCure to market Optune Pax in the U.S. for the newly approved indication.
• The 8-K discloses the approval but does not include financial results, guidance, or detailed commercial plans; investors should watch for subsequent filings or company communications for information on expected timing, revenue impact, reimbursement, and commercialization strategy.